No specific clinical trials are currently ongoing in patients with NF1 mutant melanomas, but several trials are evaluating targeted therapy in NF1 mutant solid tumors, including melanomas: (1) The MATCH screening trial evaluating trametinib for the treatment of NF1 mutant refractory solid cancers (NCT02465060); (2) the MatchMel trial which includes a cohort with NF1 mutant refractory tumors receiving trametinib, sorafenib, or everolimus (NCT02645149); and (3) the use of RMC4630 (a potent PTPN11 inhibitor) and cobmitinib in solid tumors with NF1 mutations (NCT03634982). Here, PTPN11 is linked to melanoma.